
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1567999
This article is part of the Research Topic Precision Medicine in Immunology: Targeting Inflammation to Improve Patient Care with Immune Diseases View all articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Anti-platelet factor 4 (PF4) immunothrombosis is characterized by thrombocytopenia, thrombosis and enhanced NETosis and has been described in the absence of prior heparin exposure. This case report describes a patient with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who, while under immunosuppression, developed anti-PF4-mediated immunothrombosis, with NETosis significantly elevated compared to baseline markers observed during AAV. Treatment with intravenous immunoglobulin (IVIG) led to resolution of the syndrome, marked by a reduction in NETosis markers, restoration of platelet counts, and alleviation of the hypercoagulable state. We review the epidemiology, pathogenesis, clinical manifestations, and management strategies of thrombotic anti-PF4 immune disorders, highlighting the roles of AAV and dysregulated NETosis as key triggers. Early recognition of anti-PF4-mediated immunothrombosis without prior heparin exposure is critical, as prompt treatment with IVIG and direct thrombin inhibitors can significantly improve outcomes. This case underscores the interplay between NETosis, ANCA vasculitis, and thrombotic anti-PF4 immune disorders, emphasizing the therapeutic potential of IVIG in mitigating NETosis-related complications.
Keywords: Anti-PF4 immunothrombosis, NEtosis, ANCA, IVIg, case report
Received: 28 Jan 2025; Accepted: 24 Mar 2025.
Copyright: © 2025 Kruzel-Davila, Remez, Vdovich and Akria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Etty Kruzel-Davila, Faculty of Medicine, Bar-Ilan University, Safed, Israel
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.